AXA S.A.
- SEC CIK
- 0000898427
- Latest filing
- Aug 14, 2026
ABT holding history
Abbott Laboratories in every 13F filed by AXA S.A., including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
ABT overviewAll 13F holders of ABTFull Q2 2026 holdings
- Shares (Q3 2025)
- 0
- Sold out in Q3 2025
- Value
- $0
- % of portfolio
- 0.0%
- Quarters held
- 18
- Since Q1 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q3 2025 | 0 | $0 | 0.0% | −1,200,987−100.0% | Sold out | Holders |
| Q2 2025 | 1,200,987 | $163.3M | 0.5% | +83,425+7.5% | Added | Holders |
| Q1 2025 | 1,117,562 | $148.2M | 0.5% | +8,028+0.7% | Added | Holders |
| Q4 2024 | 1,109,534 | $125.5M | 0.4% | −312,735−22.0% | Reduced | Holders |
| Q3 2024 | 1,422,269 | $162.2M | 0.5% | +38,844+2.8% | Added | Holders |
| Q2 2024 | 1,383,425 | $143.8M | 0.4% | +605,269+77.8% | Added | Holders |
| Q1 2024 | 778,156 | $88.4M | 0.3% | −636,734−45.0% | Reduced | Holders |
| Q4 2023 | 1,414,890 | $155.7M | 0.5% | −109,281−7.2% | Reduced | Holders |
| Q3 2023 | 1,524,171 | $147.6M | 0.5% | +58,985+4.0% | Added | Holders |
| Q2 2023 | 1,465,186 | $159.7M | 0.5% | −227,551−13.4% | Reduced | Holders |
| Q1 2023 | 1,692,737 | $171.4M | 0.6% | +191,861+12.8% | Added | Holders |
| Q4 2022 | 1,500,876 | $164.8M | 0.6% | +58,321+4.0% | Added | Holders |
| Q3 2022 | 1,442,555 | $139.6M | 0.5% | +186,669+14.9% | Added | Holders |
| Q2 2022 | 1,255,886 | $136.5M | 0.5% | +126,093+11.2% | Added | Holders |
| Q1 2022 | 1,129,793 | $133.7M | 0.4% | +32,644+3.0% | Added | Holders |
| Q4 2021 | 1,097,149 | $154.4M | 0.4% | +44,693+4.2% | Added | Holders |
| Q3 2021 | 1,052,456 | $124.3M | 0.3% | −821−0.1% | Reduced | Holders |
| Q2 2021 | 1,053,277 | $122.1M | 0.3% | −61,578−5.5% | Reduced | Holders |
| Q1 2021 | 1,114,855 | $133.6M | 0.4% | – | – | Holders |
Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.